Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
QUINORA vs TAMBOCOR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Quinora (quinidine) is a Class Ia antiarrhythmic agent that blocks sodium channels, prolonging the action potential duration and effective refractory period. It also exhibits anticholinergic and negative inotropic effects.
Class Ic antiarrhythmic agent; blocks sodium channels, slowing conduction velocity and prolonging refractoriness in cardiac tissues.
Treatment of atrial fibrillation and flutter,Ventricular arrhythmias,Off-label: Management of malaria (as quinine derivative)
Treatment of documented life-threatening ventricular arrhythmias (e.g., sustained ventricular tachycardia),Suppression of symptomatic atrial fibrillation/flutter (off-label)
325 mg orally every 4 to 6 hours as needed, not to exceed 4 g/day.
For atrial fibrillation/flutter: 50 mg orally every 12 hours; may increase by 50 mg every 4 days up to 300 mg/day. For life-threatening ventricular arrhythmias: 100 mg orally every 12 hours; increase by 50 mg every 4 days up to 400 mg/day.
5-7 hours; prolonged in hepatic impairment (up to 12-15 hours) and in elderly patients.
Terminal elimination half-life: 12–27 hours (mean 20 hours); prolonged to 58 hours in heart failure or renal impairment (Cr Cl < 35 m L/min).
Primarily hepatic via CYP3A4; also metabolized by CYP2C9 and CYP2E1. Active metabolites include 3-hydroxyquinidine. Renal excretion of unchanged drug accounts for 10-20% of clearance.
Hepatic metabolism via CYP2D6; active metabolite; renal excretion of unchanged drug and metabolites.
Primarily hepatic (biliary) excretion into feces (~80-90%); renal excretion of unchanged drug accounts for ~10-20%.
Renal: 85% (30% unchanged, 55% as inactive metabolites); Fecal: 5%; Biliary: negligible.
90-95% bound to plasma proteins (primarily albumin and alpha-1-acid glycoprotein).
90–95% bound to albumin and alpha-1-acid glycoprotein.
2.5-3.5 L/kg; extensive tissue distribution with high affinity for cardiac muscle.
8–10 L/kg; extensive tissue distribution (lung, heart, liver).
Oral: ~70-80% (first-pass metabolism reduces bioavailability; food may decrease rate but not extent).
Oral: 85–90% (first-pass metabolism minimal).
GFR 30-50 m L/min: reduce dose by 25%; GFR <30 m L/min: avoid use or prolong dosing interval to every 8 hours.
Cr Cl >50 m L/min: no adjustment; Cr Cl 35-50 m L/min: 50 mg every 12 hours; Cr Cl <35 m L/min: 100 mg every 24 hours or 50 mg every 12 hours with caution.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
Child-Pugh class A: no adjustment; Child-Pugh class B: reduce dose by 25-50%; Child-Pugh class C: contraindicated or use with extreme caution.
10-15 mg/kg/dose orally every 4-6 hours; maximum 60 mg/kg/day.
Dosing not established; limited data: 1-3 mg/kg/day orally divided every 8-12 hours; maximum 6 mg/kg/day.
Start at lowest effective dose; consider 325 mg every 6-8 hours due to increased risk of accumulation.
Start at 50 mg every 12 hours; increase slowly with close monitoring of plasma levels and ECG; consider lower doses due to reduced renal function.
May cause potentially fatal ventricular arrhythmias (e.g., torsades de pointes) due to QT prolongation. Reserve for patients with life-threatening arrhythmias. Monitor ECG and serum electrolytes. Discontinue if QT interval >50% baseline or QRS duration increases >25%.
May increase mortality in patients with structural heart disease (e.g., post-MI, cardiomyopathy). Reserved for life-threatening arrhythmias.
May cause cinchonism (tinnitus, headache, visual disturbances). Risk of QT prolongation and torsades de pointes, especially in patients with hypokalemia, bradycardia, or structural heart disease. Hemolytic anemia may occur in G6PD deficiency. Can exacerbate heart failure due to negative inotropic effects. Drug interactions: hepatic enzyme inducers/inhibitors, other QT-prolonging drugs.
Proarrhythmic effects including new or worsened ventricular arrhythmias,Use caution in patients with conduction abnormalities (e.g., SA node dysfunction, bundle branch block),Heart failure exacerbation due to negative inotropic effects,Electrolyte disturbances (hypokalemia, hypomagnesemia) should be corrected,Plasma monitoring recommended due to narrow therapeutic index
History of QT prolongation or torsades de pointes with quinidine. Myasthenia gravis (due to anticholinergic effects). Complete AV block without pacemaker. Known hypersensitivity (including thrombocytopenia). Major contraindication in malaria caused by Plasmodium falciparum with severe adverse reactions.
Second- or third-degree AV block (unless pacemaker in place),Bifascicular block or distal conduction blocks,Cardiogenic shock or severe hypotension,Pre-existing prolonged QT interval,History of ventricular arrhythmias associated with structural heart disease
Grapefruit juice increases quinidine levels; avoid concurrent use. Food does not affect absorption significantly; take with or without food. High-fat meals may delay absorption.
Grapefruit juice increases flecainide AUC by 15-40% and should be avoided. High-fat meals may delay absorption but do not significantly alter overall exposure. No other specific dietary restrictions.
In first trimester, associated with increased risk of spontaneous abortion and congenital anomalies including cardiovascular and neural tube defects. Second and third trimester exposure may cause premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment.
FDA Pregnancy Category C. Flecainide crosses the placenta. First trimester: Limited human data; animal studies show fetal toxicity at maternally toxic doses. Second and third trimesters: Risk of fetal arrhythmia, including tachycardia or heart block; may require fetal echocardiography. Avoid in pregnancy unless benefit outweighs risk.
Excreted into breast milk; M/P ratio unknown. Due to risk of serious adverse reactions in nursing infants including kernicterus in neonates with G6PD deficiency, contraindicated during breastfeeding.
Flecainide is excreted into breast milk. Milk-to-plasma ratio approximately 2.5 (range 1.4–3.8). Infant exposure estimated at 3–5% of maternal weight-adjusted dose. Monitor infant for bradycardia, arrhythmia, and feeding difficulties. Use with caution; alternative agents preferred.
Increased volume of distribution and renal clearance during pregnancy may require dose increase; therapeutic drug monitoring recommended to maintain efficacy.
Increased plasma volume and renal clearance in pregnancy may reduce flecainide levels. Monitor therapeutic drug levels and ECG; dose adjustments may be needed (typically increased dose required). Titrate based on arrhythmia control and toxicity. Postpartum: dose may need reduction as clearance normalizes.
Quinora (quinidine) is a class Ia antiarrhythmic; monitor for QT prolongation and torsades de pointes. Use with caution in heart failure, renal impairment, and hepatic dysfunction. Check serum potassium and magnesium levels before initiation. Watch for cinchonism (tinnitus, headache, blurred vision) at high doses. Avoid use with other QT-prolonging drugs. Therapeutic drug monitoring is recommended (target 2-6 mcg/m L).
Tambocor (flecainide) is a class Ic antiarrhythmic used for life-threatening ventricular arrhythmias and paroxysmal atrial fibrillation/flutter. It has a narrow therapeutic index and requires ECG monitoring for QRS prolongation (>140 ms) or new arrhythmias. Contraindicated in ischemic heart disease due to increased mortality (CAST trial). Adjust dose in renal impairment (Cr Cl < 50 m L/min: start at 50 mg q12h). Proarrhythmic risk is highest in patients with structural heart disease or reduced EF. Monitor trough levels (therapeutic range: 0.2-1.0 mcg/m L).
Take exactly as prescribed; do not skip doses or double up if missed.,Report any signs of allergic reaction (rash, fever, difficulty breathing) or unusual bleeding/bruising.,Avoid grapefruit juice as it may increase quinidine levels.,Contact your doctor if you experience dizziness, fainting, or palpitations.,Do not stop abruptly; taper as directed to avoid rebound arrhythmias.,Tell all healthcare providers you are taking quinidine.
Take exactly as prescribed; do not stop or change dose without consulting your doctor.,Report any new or worsening chest pain, palpitations, fainting, or difficulty breathing immediately.,Avoid grapefruit juice as it can increase flecainide levels and risk of side effects.,Take with or without food; maintain consistent timing to keep levels stable.,Do not crush or chew extended-release capsules; swallow whole.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about QUINORA vs TAMBOCOR, answered by our medical review team.
QUINORA is a Antiarrhythmic Agent that works by Quinora (quinidine) is a Class Ia antiarrhythmic agent that blocks sodium channels, prolonging the action potential duration and effective refractory period. It also exhibits anticholinergic and negative inotropic effects.. TAMBOCOR is a Antiarrhythmic Agent that works by Class Ic antiarrhythmic agent; blocks sodium channels, slowing conduction velocity and prolonging refractoriness in cardiac tissues.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between QUINORA and TAMBOCOR depend on the specific clinical indication. These are both Antiarrhythmic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of QUINORA is: 325 mg orally every 4 to 6 hours as needed, not to exceed 4 g/day.. The standard adult dose of TAMBOCOR is: For atrial fibrillation/flutter: 50 mg orally every 12 hours; may increase by 50 mg every 4 days up to 300 mg/day. For life-threatening ventricular arrhythmias: 100 mg orally every 12 hours; increase by 50 mg every 4 days up to 400 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between QUINORA and TAMBOCOR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. QUINORA is classified as Category C. In first trimester, associated with increased risk of spontaneous abortion and congenital anomalies including cardiovascular and neural tube defects. Second and third trimester exp. TAMBOCOR is classified as Category C. FDA Pregnancy Category C. Flecainide crosses the placenta. First trimester: Limited human data; animal studies show fetal toxicity at maternally toxic doses. Second and third trime. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.